<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04136015</url>
  </required_header>
  <id_info>
    <org_study_id>TKIs-cml-001</org_study_id>
    <nct_id>NCT04136015</nct_id>
  </id_info>
  <brief_title>Early Conversion of Dasatinib in CML-CP Patients</brief_title>
  <official_title>A Prospective Study on Early Conversion of Dasatinib in CML-CP Patients Who Have Not Early Molecular Response on Imatinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic myeloid leukemia (CML) is a malignant disease of acquired hematopoietic stem cells.
      The BCR-ABL fusion gene is the pathogenic basis of CML. Tyrosine kinase inhibitors (TKIs) are
      targeted drugs for this fusion protein. With the wide clinical application of TKIs, the
      efficacy of CML patients has been greatly improved. However, there are still a significant
      number of patients who have poor response to the first generation of TKI drugs, imatinib,
      most of them have early molecular response failures (BCR-ABL（IS）＞10% at 3 or 6 months) ，which
      means lower rates of molecular response, increased risk of progression, and higher overall
      survival. For them, the early conversion of dasatinib might be a better choice.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 22, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MMR in 1 year</measure>
    <time_frame>1 year</time_frame>
    <description>MMR(BCR/ABL(IS)&lt;0.1%) at 12 months after switching to dasatinib for patients who did not achieve optimal treatment with imatinib for 3 to 6 months.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Validity and Safety</condition>
  <arm_group>
    <arm_group_label>Dasatinib group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Imatinib group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib 100 MG</intervention_name>
    <description>The CML-CP patients with early(3m to 6m) molecular response failure on imatinib,Conversion dasatinib group or Imatinib group</description>
    <arm_group_label>Dasatinib group</arm_group_label>
    <arm_group_label>Imatinib group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        CML-CP patients treated with imatinib failed to achieve the best therapeutic
        effect（BCR/ABLIS＞10.00% in 3m or BCR/ABLIS＞1.00% in 6m）convert to dasatinib.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.18-65 years old； 2.CML-CP,and Imatinib treatment longest for 6 months ； 3.Q-pcr
        monitoring of BCR/ABLIS failed to achieve the best therapeutic effect（BCR/ABLIS＞10.00% in
        3m or BCR/ABLIS＞1.00% in 6m）； 4.No previous history of malignant tumor; 5.Informed consent
        of the patient or his legal representative

        Exclusion Criteria:

          1. History of CML-CP or CML-AP;

          2. Resistant to dasatinib,or treatment with imatinib more than 6 months;

          3. Received allogeneic hematopoietic stem cell transplantation,or immunotherapy;

          4. woman who is pregnant or nursing

          5. Combined with other serious organic diseases, serious arrhythmia, pulmonary
             hypertension, cardiomyopathy, serious autoimmune diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>NanfangH</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 21, 2019</study_first_submitted>
  <study_first_submitted_qc>October 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2019</study_first_posted>
  <last_update_submitted>October 21, 2019</last_update_submitted>
  <last_update_submitted_qc>October 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>xuna</investigator_full_name>
    <investigator_title>Associate chief physician</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

